---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort C"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort C. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 77 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/bond-003-cohort-c"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: BOND-003 cohort C

<a id="heading-3.1.1"></a>

## 3.1.1 BOND-003 Cohort C

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Registry objective: complete response at any time in BCG-unresponsive CIS

> “To determine the Complete Response rate at any time in patients with BCG-unresponsive CIS with or without concomitant HG Ta/T1 papillary disease.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.1-2"></a>

#### Publication objective: response, safety, and tolerability

> “We evaluated the response and safety/tolerability of cretostimogene in patients with high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.1-3"></a>

#### Trial-in-progress objective: confirmation of monotherapy activity

> “This single arm phase 3 study was launched to confirm the clinical activity of monotherapy CG0070 in patients with NMIBC unresponsive to BCG.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Centres and regions

> “BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.”
> “Sites were selected through a study team-led qualification process that evaluated feasibility, protocol alignment, operational capabilities, and regulatory readiness, as applicable.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.2-2"></a>

#### Countries named in the trial-in-progress report

> “The study is being conducted in the United States, Japan, South Korea, Australia, and Taiwan.”

Source: [Uchio et al. (2021)](https://cgoncology.com/wp-content/uploads/2025/11/2021_sitc_bond-003_poster-2.pdf)

<a id="topic-3.1.1.2-3"></a>

#### Proportion of participants enrolled in the United States

> “63.4% of patients in US”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.2-4"></a>

#### Enrollment period

> “Between Oct 9, 2020, and Aug 3, 2023”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.2-5"></a>

#### Enrollment status of Cohort C

> “Cohort C is closed to enrollment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.2-6"></a>

#### Latest efficacy data cutoff and median follow-up

> “As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1)”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “Efficacy data cutoff 23JUN2025”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.2-7"></a>

#### Next data release for Cohort C

> “Long-term Data Anticipated 2027”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Single-arm, open-label phase 3 design with separately analyzed cohorts

> “This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy.”
> “Cohort C and Cohort P will be analyzed and reported separately.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.3-2"></a>

#### Global trial in BCG-unresponsive CIS-containing and papillary disease

> “BOND-003 is a global, open-label, single-arm Phase 3 clinical trial designed to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients that have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta or T1 papillary tumors.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.3-3"></a>

#### Response assessment schedule and central confirmation

> “Response assessments include cystoscopy (biopsy as indicated) & cytology every 3 months for first 2 years and every 6 months starting Year 3; all responses are centrally confirmed”
> “All visible disease was resected prior to treatment”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Mandatory bladder mapping at 12 months

> “Patients undergo urine cytology and cystoscopy every 3 months for first 2 years, as well as mandatory bladder mapping at month 12.”
> “All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Design stated by the company to follow the 2018 FDA guidance

> “Trial designed to be compliant with 2018 FDA guidance”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion criteria in the publication

> “We enrolled patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0-2 and pathologically confirmed, high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without resected high-grade Ta or T1 disease.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.4-2"></a>

#### Definition of BCG-unresponsive disease

> “BCG-UR defined as persistent or recurrent CIS +/- Ta/T1 within 12 months of BCG therapy per FDA guidance”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.4-3"></a>

#### Registry inclusion criteria for Cohort C

> “Pathologically confirmed relapsed or persistent CIS (with or without HG Ta or HG T1 disease) within 12 months of completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, HG Ta, HG T1, or a combination of these HGUC pathologies).”
> “Pathological confirmation of BCG unresponsive CIS within 8 weeks of study enrollment.”
> “CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.”
> “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy according to Investigator assessment.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.4-4"></a>

#### Registry key exclusion criteria

> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer.”
> “Has had prior systemic treatment (with the exception of checkpoint inhibitor therapy), radiation therapy, or surgery for bladder cancer other than TURBT or bladder biopsies.”
> “Has received systemic anti-cancer therapy, including investigational agents, within 4 weeks of Day 1.”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of cretostimogene.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Dose and schedule in the publication

> “Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.5-2"></a>

#### Dose and schedule in the company annual report

> “The initial induction course of therapy is six weekly doses of cretostimogene containing 1x1012 VPs per milliliter.”
> “Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at the same concentration every three months for the first 12 months and every six months for the next 24 months.”
> “Patients who do not achieve a CR after the first induction course may receive a second induction course of six weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.5-3"></a>

#### Treatment courses

| Course | Schedule |
| --- | --- |
| Induction | “Weekly x 6” |
| Maintenance, year 1 | “Weekly x 3 Q3M for Year 1” |
| Maintenance, years 2 to 3 | “Weekly x 3 Q6M for Year 2-3” |
| Second induction | “Weekly x 6 for non-responders” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Registry arm description: DDM pretreatment and dosing weeks

> “Cretostimogene will be administered intravesically following a series of bladder washes with 5% DDM and normal saline.”
> “If the patient has disease recurrence at Week 13, they will receive another cycle of 6 weekly treatments.”
> “every 6 months starting at Weeks 73, 74, and 75 through Weeks 157, 158, and 159 until the tumor returns or study treatment is completed at Week 159.”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.5-5"></a>

#### Instillation process used in Cohort C and in later studies

> “All studies beyond BOND-003 Cohort C use optimized instillation protocol”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

> “Prior to the administration of cretostimogene, patients undergo a saline wash and are then pretreated with n-Dodecyl-ß-D-maltoside (DDM) through IVE delivery.”
> “We have now streamlined this process and eliminated the saline and DDM wash steps.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Complete Response at Any Time as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint and secondary endpoints in the trial-in-progress report

> “The primary endpoint of the study is CR at anytime on study.”
> “Secondary endpoints will include CR at 12 m, duration of response, progression free survival, cystectomy free survival and safety.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary endpoint in the company annual report

> “The primary endpoint of the BOND-003 trial is CR at any time subsequent to induction.”
> “We designed this trial in light of the 2018 FDA guidance, and the revised draft guidance in August 2024, which defines BCG-unresponsive disease states and says that single-arm trials that assess CR rate as the primary endpoint, taking DOR into account, may be appropriate for full approval.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.6.1-3"></a>

##### Registry secondary outcomes for Cohort C

> “Cohort C: Duration of response (DOR)”
> “Median duration of response in patients with a CR or PR in subjects”
> “Cohort C:Complete Response rate at 12 months”
> “Cohort C and Cohort P : Cystectomy free survival”
> “Cohort C: Assess overall survival”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.6.1-4"></a>

##### Definition of complete response used in the trial

> “CR is defined as having a negative cystoscopy, a negative urine cytology, and a negative biopsy.”
> “In addition, all patients at 12-month timepoint undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR and detect potential occult disease in the bladder.”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.6.1-5"></a>

##### Cystectomy-free survival: definition and rationale

> “Cystectomy-free survival defined as time from first dose to radical cystectomy or censoring”
> “Cystectomy-free survival is an important complementary endpoint that captures both disease control and bladder preservation for patients with high-risk BCG-unresponsive NMIBC”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.6.1-6"></a>

##### FDA 2018 guidance: complete response rate as the primary endpoint of a single-arm trial

> “a single-arm clinical trial with complete response rate and duration of response as the primary endpoint can provide primary evidence of effectiveness to support a marketing application.”
> “Currently, single-arm trials are appropriate for assessment of therapies for patients with BCG-unresponsive disease (CIS with or without resected papillary disease) because, currently, no effective medical therapies are available and the only alternative is radical cystectomy.”
> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC should be the complete response rate in patients with CIS.”
> “The natural history of CIS is well understood, and the complete response rate is negligible in the absence of therapy.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### FDA 2018 guidance: confidence interval, duration of response, and assessment at 3 months

> “the lower bound of the 95 percent confidence interval around the observed response rate should rule out a clinically unimportant complete response rate.”
> “A high complete response rate is not meaningful if the response duration is short.”
> “However, the trial design should prespecify whether patients with CIS who do not achieve a complete response at their 3-month assessments should discontinue the investigational drug(s) because of the risk of progression.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.6.1-8"></a>

##### FDA 2024 draft guidance: complete response as an interpretable single-arm endpoint

> “making complete response (CR) an interpretable endpoint in the single arm setting.”
> “primary endpoint, supported by duration of response, can provide primary evidence of”
> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC”
> “with CIS should be CR rate.”
> “A high CR rate is not meaningful if the response duration is short.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.1.6.1-9"></a>

##### International Bladder Cancer Group 2016: single-arm designs and clinically meaningful response rates

> “Single-arm designs may be relevant for the BCG-unresponsive population.”
> “Given the high risk of disease progression, a placebo-controlled arm is not ethical.”
> “For patients with BCG-unresponsive CIS, we recommend an initial CR rate of 50% at 6 months and durable response rates of 30% at 12 months and 25% at 18 months as clinically meaningful.”
> “In a recent FDA–AUA public workshop, some panel members felt that an initial CR rate of 40% to 50% at 6 months and a durable response rate of at least 30% for 18 to 24 months, with the lower bound of the 95% CI excluding 20%, could be clinically meaningful in the BCG-refractory CIS population.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.1.6.1-10"></a>

##### SITC and International Bladder Cancer Group 2023: complete response rate and duration in single-arm trials

> “For populations with CIS, CR rate and duration are clinically meaningful end points.”
> “Random assignment in this setting may be less acceptable to patients/providers, and single-arm trial designs have been permitted by the US Food and Drug Administration (FDA)”
> “Per FDA guidance, CR rate and duration should be benchmarked against historical agents or modern options (eg, valrubicin, pembrolizumab, gemcitabine and docetaxel, or nadofaragene firadenovec).”

Source: [Kamat et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10713193/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment in the registry

> “Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C.”
> “Single treatment arm that enrolled 115 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease”

Source: [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment in the trial-in-progress report

> “110 patients with BCG-unresponsive CIS with or without concurrent Ta or T1 disease will be treated with intravesical (IVE) CG0070 at a dose of 1x1012 vp.”

Source: [Uchio et al. (2020)](https://cgoncology.com/wp-content/uploads/2025/11/2020_suo_bond-003_poster-1.pdf)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants enrolled, treated, and analyzed for efficacy

> “115 patients were enrolled in the study and 112 received cretostimogene”
> “complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.7.1-4"></a>

##### Efficacy-evaluable and safety populations

> “110 efficacy evaluable patients”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

> “Subjects in Safety Dataset”
> “N=112”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Efficacy and safety analysis populations

> “The primary endpoint was centrally confirmed complete response at any time in patients who received at least one dose of cretostimogene and completed the 3-month assessment; safety was assessed in those who received at least one dose of cretostimogene.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.7.2-2"></a>

##### Central confirmation, landmark and Kaplan-Meier analyses

> “Efficacy analysis centrally confirmed.”
> “Analysis based on both landmark CR rate assessed in clinical trial and CR by Kaplan-Meier estimate.”
> “Local : Central concordance: 97.1% of assessments”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Cystectomy-free survival analysis set

> “CFS calculated from first study treatment to cystectomy or censoring, whichever occurred first in the efficacy analysis set”

Source: [Steinberg et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/02/F13_BOND-003-Cohort-C-Cystectomy_Gary-Steinberg_Final.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Population labeled intention to treat for the 24-month landmark

> “High landmark CR at 24 mo in ITT population of 41.8% (46/110)”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Subgroup definitions for prior-therapy analyses

> “Second-Line: patients diagnosed with BCG-UR who received an additional therapy after adequate BCG.”
> “Prior Intervening Chemotherapy: adjuvant IVE chemotherapy before or after adequate BCG.”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Screening, enrollment, and treatment

> “Between Oct 9, 2020, and Aug 3, 2023, 165 patients were assessed for eligibility; 115 patients were enrolled in the study and 112 received cretostimogene.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.1-2"></a>

##### Treatment completion, discontinuation, and missed doses

> “97.3% received all protocol defined treatments”
> “No treatment related discontinuations”
> “Unrelated AE leading to treatment discontinuation was Hematuria (Grade 2).”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

> “no tx-related discontinuations; few missed (1.8%) or delayed (7.1%) doses”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.1-3"></a>

##### Radical cystectomy after recurrence or progression

> “18 patients underwent RC post-disease recurrence (n=12) or progression (n=6)”
> “1 additional patient had RC for UTUC”

Source: [Steinberg et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/02/F13_BOND-003-Cohort-C-Cystectomy_Gary-Steinberg_Final.pdf)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Sex and age in the publication

> “83 (74%) were male and 29 (26%) were female; median age was 74·0 years (IQR 68·5-79·5).”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.2-2"></a>

##### Demographics and disease characteristics, safety population

| Characteristic | n or value | % |
| --- | --- | --- |
| Male | “83” | “74.1” |
| Female | “29” | “25.9” |
| Age, mean (SD), years | “72.9 (9.19)” | |
| Age, median (range), years | “74.0 (43-90)” | |
| Age under 65 years | “19” | “17.0” |
| Age 65 to under 75 years | “43” | “38.4” |
| Age 75 years or older | “50” | “44.6” |
| Prior BCG instillations, median (range) | “12 (7 – 66)” | |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least 1 prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Race, age group, and prior therapy summary

> “White (62%)”
> “> 65 years (83%)”
> “Prior chemotherapy (41%)”
> “Systemic Immunotherapy (6%)”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Prior BCG exposure and intervening therapy

> “These patients received a median of 12 prior BCG doses, some as high as 66. Prior intervening therapy also included intravesical chemotherapy (41.1%) and systemic immunotherapy (6.3%).”

Source: [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and)

<a id="topic-3.1.1.8.2-5"></a>

##### ECOG performance status, January 2025 data cutoff

| ECOG performance status | n | % |
| --- | --- | --- |
| 0 | “95” | “84.8” |
| 1 | “17” | “15.2” |

Source: [Bivalacqua (2025)](https://cgoncology.com/wp-content/uploads/2025/11/Updated_Clinical_and_Translational_Results_from_BOND-003_Cohort_C.pdf)

<a id="topic-3.1.1.8.2-6"></a>

##### Second-line and prior intervening chemotherapy subgroups

> “23/110 (21%) patients: Second-Line BCG-UR”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “>1 course of IVE gemcitabine (11/34; 32%)”
> “IVE gemcitabine-docetaxel (16/34; 47%)”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary endpoint: complete response at any time, June 23, 2025 cutoff

> “As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients.”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

> “With a median follow-up time of 25.8 months, CR rate at any time is 75.5% (83/110) (95% CI 66.3-83.2%)”

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.3-2"></a>

##### Company statement on the primary endpoint

> “BOND-003 Cohort C met its primary endpoint with statistical significance, exceeding historic and contemporary clinical benchmarks.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-3"></a>

##### Complete response at 12 and 24 months, June 23, 2025 cutoff

| Landmark | CR rate (95% CI) | Participants in CR | CR by Kaplan-Meier estimate (95% CI) |
| --- | --- | --- | --- |
| 12 months | “46.4% (36.9, 56.1)” | “51 out of 110 patients” | “50.7% (40.9, 59.8)” |
| 24 months | “41.8% (32.5, 51.6)” | “46 out of 110” | “42.4% (32.7, 51.7)” |

Source: [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf)

<a id="topic-3.1.1.8.3-4"></a>

##### Complete response at 12 months: confidence interval reported in later presentations

> “46.4% (36.8, 56.1)”
> “Efficacy data cutoff as of 23JUN2025”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-5"></a>

##### Responders added at the 24-month assessment

> “All 9 ongoing CRs remained in response at the 24-month assessment, as well as 3 additional patients confirmed to be in CR at Month 24 after further follow-up and central pathologic adjudication.”

Source: [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3)

<a id="topic-3.1.1.8.3-6"></a>

##### Duration of response, June 23, 2025 cutoff

> “Median DoR is 27.9 months and ongoing (95% CI 14.3-NE)”
> “Median follow-up of 25.8 months”
> “Estimated DOR Probability at 12 Months 64.2% (95% CI: 52.2-73.8)”
> “Estimated DOR Probability at 24 Months 60.1% (95% CI: 48.2-70.0)”
> “90% of patients in CR at 12 months, projected to remain in CR at 24 months”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

> “12- and 24-month duration of response (DOR) was 64.2% (95% CI 52.2–73.8) and 60.1% (95% CI 48.2–70.0), respectively.”
> “Median DOR is at least 27.9 months and is ongoing, with approximately 90% of patients in response at 12 months maintaining durable responses at 24 months, and one patient disease-free beyond 51 months.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-7"></a>

##### Duration of response rates attributed to the June 23, 2025 cutoff in September 2025

> “The study reported 75.5% CR at any time and 41.8% at 24 months with 46 confirmed CRs as of the cutoff date of June 23, 2025. The estimated 12- and 24-month duration of response (DOR) rates are 64.1% and 58.3%, respectively. Median DOR is 28 months and is ongoing.”

Source: [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and)

<a id="topic-3.1.1.8.3-8"></a>

##### Response after second induction

> “50.0% of patients reinduced with oncolytic immunotherapy converted to CR”
> “64.3% remain in durable response after conversion to CR”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

<a id="topic-3.1.1.8.3-9"></a>

##### Progression to muscle-invasive disease

> “96.4% (106/110) free from progression to ≥ T2 disease”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

> “96.6% of patients were free from progression to muscle invasive bladder cancer at 48 weeks and 96 weeks.”
> “we also observed a very low rate of progression to muscle-invasive bladder cancer, with only 3.4% of patients progressing during the study.”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

<a id="topic-3.1.1.8.3-10"></a>

##### Cystectomy-free survival

> “83.6% (92/110) did not undergo RC post recurrence or progression”
> “Median CFS not reached in the efficacy analysis set or any subgroups”
> “12-month: 89.2% (95% CI 81.3-93.9)”
> “24-month: 81.3% (95% CI 71.8-87.8)”
> “Based on Kaplan–Meier estimates”

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-11"></a>

##### Radical cystectomy: timing and pathologic stage

| Measure | Value |
| --- | --- |
| Cystectomy any time after first recurrence, n (%) | “18 (16.4%)” |
| Cystectomy within the first year of recurrence, n (%) | “17 (15.5%)” |
| Weeks from recurrence or progression to cystectomy, median (Q1, Q3) | “20.0 (14.4, 26.7)” |
| Stage T0, n (%) | “1 (0.9)” |
| Stage CIS, n (%) | “9 (8.2)” |
| Stage HG Ta, n (%) | “1 (0.9)” |
| Stage T1, n (%) | “4 (3.6)” |
| Stage T2A, n (%) | “1 (0.9)” |
| Stage T2B, n (%) | “1 (0.9)” |
| Stage N2, n (%) | “1 (0.9)” |
| Participants with T0 or NMIBC at cystectomy | “15/18 (83.3%) were T0 or NMIBC” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.3-12"></a>

##### Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation

> “85% CFS and 97% PFS at 24 mo.”

Source: [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf)

<a id="topic-3.1.1.8.3-13"></a>

##### Complete response in second-line and prior intervening chemotherapy subgroups

> “23/110 (21%) patients: Second-Line BCG-UR”
> “CR rate at any time: 69.6% (16/23)”
> “34/110 (31%) patients Prior Intervening Chemotherapy, with”
> “CR rate at any time: 64.7% (22/34)”

Source: [Clinton et al. (2026a)](https://cgoncology.com/wp-content/uploads/2026/09/NSAUA_2026_BOND-003_CohortC_Second_Line_Poster.pdf)

<a id="topic-3.1.1.8.3-14"></a>

##### Exploratory urinary tumor DNA analysis

> “Baseline utDNA available for 60 (53%) patients enrolled on BOND-003.”
> “Baseline utDNA did not predict the 24-mo. CR (p= 0.120).”
> “Week 13 urine was utDNA +ve in only 15 (31%) and –ve in 33 (69%) and predicted 24 mo. RFS.”
> “60% for MRD -ve and 30% for MRD +ve patients (p=0.019).”

Source: [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf)

<a id="topic-3.1.1.8.3-15"></a>

##### Complete response and duration of response at the September 30, 2024 cutoff

> “achieved a 74.5% complete response (CR) at any time in high-risk BCG-unresponsive NMIBC. As of the data cutoff of September 30, 2024, by Kaplan-Meier estimate, 63.5% and 56.6% of patients remained in response at 12 months or greater and at 24 months or greater, respectively, while the median DOR was not reached but exceeds 27 months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.8.3-16"></a>

##### Complete response at 24 months and duration of response at the March 14, 2025 cutoff

> “33.7% (24.8, 43.8)”
> “34 out of 101 evaluable patients, pending 9 ongoing CRs that have yet to reach 24-month assessment”
> “Estimated DOR Probability at 12 Months 64.1% (95% CI: 52.4-73.7)”
> “Estimated DOR Probability at 24 Months 58.3% (95% CI: 46.3-68.5)”
> “Efficacy data cutoff as of 14MAR2025”

Source: [Tyson (2025a)](https://cgoncology.com/wp-content/uploads/2025/11/AUA_2025_BOND-003_Cohort_C_Late-Breaking_Plenary.pdf)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-related adverse events in the publication

> “71 (63%) of 112 patients had at least one treatment-related adverse event, the most common being bladder spasm in 28 (25%) patients, pollakiuria in 25 (22%) patients, and micturition urgency in 23 (21%) patients; there were no grade 3 or 4 treatment-related adverse events and no treatment-related discontinuations or deaths.”
> “Two (2%) patients had serious treatment-related adverse events (one non-infective cystitis and one urinary bladder haemorrhage, both grade 2).”

Source: [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/)

<a id="topic-3.1.1.8.5-2"></a>

##### Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff

| Preferred term (MedDRA v.26.1) | Any grade, n (%) | Grade 3 or higher, n (%) |
| --- | --- | --- |
| At least 1 treatment-related adverse event | “71 (63.4%)” | “0 (0)” |
| Bladder spasm | “28 (25.0%)” | “0 (0)” |
| Pollakiuria | “25 (22.3%)” | “0 (0)” |
| Urgency | “23 (20.5%)” | “0 (0)” |
| Dysuria | “21 (18.8%)” | “0 (0)” |
| Hematuria | “15 (13.4%)” | “0 (0)” |

Source: [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf)

<a id="topic-3.1.1.8.5-3"></a>

##### Severity, resolution, and serious treatment-related adverse events

> “Most AEs were Grade 1-2”
> “0% Grade ≥ 3 TRAEs or deaths”
> “Median time to TRAE resolution: 1 day”
> “1.8% (n=2) had serious treatment-related AEs (Grade 2)”
> “Treatment-related SAEs were noninfective cystitis (Grade 2) and clot retention (Grade 2).”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

> “The median time to resolution of related adverse events was 1 day (IQR 0–7).”

Source: [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

> “Two patients (1.8%) had SAEs, including Grade 2 noninfective cystitis, and Grade 2 clot retention, both of which resolved.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: limitations of the BOND-003 Cohort C evidence

- Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
- Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
- Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
- Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
- Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
- Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
- Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download); [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf); [Tyson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508433/); [Tyson et al. (2025d)](https://cgoncology.com/wp-content/uploads/2025/12/SUO_2025_Final_Results_BOND_003_Cohort_C_ePoster.pdf); [Kassouf et al. (2026)](https://cgoncology.com/wp-content/uploads/2026/06/CUA_2026-BOND%E2%80%91003_Cohort_C_Podium.pdf); [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf); [Dinney (2026c)](https://cgoncology.com/wp-content/uploads/2026/09/IBCN_2026_BOND-003_CohortC_and_Urinary_Tumor_DNA_Podium.pdf); [ClinicalTrials.gov NCT04452591](https://clinicaltrials.gov/study/NCT04452591); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [CG Oncology BOND-003 24-month data press release (2025)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-continues-demonstrate-best-disease-durability-and); [CG Oncology Lancet Oncology publication press release (2026)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003); [CG Oncology investor presentation (2026)](https://ir.cgoncology.com/static-files/16380a7a-42d9-40fc-a2a5-03e0b5235ed3); [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

<a id="topic-3.1.1.9-2"></a>

#### FDA 2024 draft guidance: limits of single-arm trials

> “Time-to-event endpoints are uninterpretable in a single-arm trial.”
> “Lack of a comparator arm can make differentiating drug-related adverse events from”
> “those due to the underlying disease or other causes challenging.”
> “Standard of care intravesicular and systemic treatments exist for patients with BCG”
> “unresponsive NMIBC allowing for an RCT design.”

Source: [FDA BCG-unresponsive NMIBC draft guidance (2024)](https://www.fda.gov/media/101468/download)

<a id="topic-3.1.1.9-3"></a>

#### FDA 2018 guidance: cystectomy delay as an endpoint

> “Although delay in radical cystectomy is considered a direct patient benefit, the variations in patient and health care provider preferences can confound the interpretation of this endpoint in randomized trials and particularly in single-arm trials.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.1.9-4"></a>

#### Progression as an endpoint in BCG-unresponsive trials

> “Also, although progression is actually the clinically meaningful end point in this patient population, it is not practical to power these trials for progression.”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.1.9-5"></a>

#### Company risk statements on topline data and regulatory sufficiency

> “Topline and preliminary data also remain subject to audit and verification procedures that may result, in the final data being materially different from the topline or preliminary data we previously published.”
> “we cannot be certain that our Phase 3 BOND-003 Cohort C trial for cretostimogene will be sufficient to support regulatory approval, even if we believe the results are sufficiently positive”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.1.9-6"></a>

#### Sponsor funding

> “Research funded by CG Oncology, Inc.”

Source: [Preston (2026)](https://cgoncology.com/wp-content/uploads/2026/10/NEAUA_2026_BOND-003_CohortC_Durable_24Mo_Outcomes_Podium.pdf)

Additional sources: [Robesti et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42508430/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
